Dare Bioscience, Inc. entered into a Traditional Royalty Purchase Agreement and a Synthetic Royalty Purchase Agreement with XOMA, where XOMA paid $22.0 million to Dare and will make additional payments if total payments under the agreements exceed $88.0 million.